QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gold, D. T Articles by Ettinger, M. P Search for Related Content PubMed PubMed Citation Articles by Gold, D. T Articles by Ettinger, M. P

WOMEN'S HEALTH

How Can Osteoporosis Patients Benefit More from Their Therapy? Adherence Issues with Bisphosphonate Therapy

Associate Professor of Medical Sociology, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC

Ivy M Alexander, PhD C-ANP

Associate Professor of Nursing, Yale University, New Haven, CT

Mark P Ettinger, MD FACR

Medical Director Emeritus, Radiant Research and The Regional Osteoporosis Center, Stuart, FL

Reprints: Dr. Gold, Box 3003, Duke University Medical Center, Durham, NC 27710-0001, fax 919/684-8569, dtg{at}geri.duke.edu

OBJECTIVE: To review the evidence on adherence with bisphosphonates and evolving dosing strategies for osteoporosis treatment.

DATA SOURCES: Articles were identified by searching MEDLINE (1975-December 2005) using the following terms: osteoporosis, postmenopausal, fracture, adherence, compliance, persistence, drug therapy, bisphosphonates, alendronate, risedronate, ibandronate, and zoledronate. Additional data included bibliographies from identified articles.

STUDY SELECTION AND DATA EXTRACTION: All pertinent English-language articles that discussed adherence issues in patients with osteoporosis were included. Both those that reviewed overall issues of medication adherence in osteoporosis and those that focused specifically on adherence to bisphosphonates were included, as were articles that addressed strategies for overcoming nonadherence.

DATA SYNTHESIS: Inadequate diagnosis and treatment of osteoporosis result in a higher risk of fractures than is necessary. Even patients who are diagnosed and beginning treatment often do not persist with their osteoporosis medication because they perceive their fracture risk to be low and, given the asymptomatic nature of osteoporosis, do not experience the benefit of symptom reduction after taking the drugs. Factors that affect adherence to osteoporosis therapy include drug costs, adverse effects, dosing frequency, disease education, patient follow-up, and patient involvement in treatment decisions.

CONCLUSIONS: By considering and implementing strategies that can improve adherence and persistence, primary care providers and pharmacists (via counseling) may enhance long-term outcomes for patients with osteoporosis.

Key Words: adherence, fracture, osteoporosis

Published Online, May 30, 2006. www.theannals.com, DOI 10.1345/aph.1G534

This article has been cited by other articles:

				M. Mulgund, K. A. Beattie, A. K. O. Wong, A. Papaioannou, and J. D. Adachi Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture Therapeutic Advances in Musculoskeletal Diseases, October 1, 2009; 1(1): 5 - 11. [Abstract] [PDF]